Literature DB >> 7994252

Complete remission following donor leukocyte infusion in ALL relapsing after haploidentical bone marrow transplantation.

A Ferster1, W Bujan, T Mouraux, C Devalck, P Heimann, E Sariban.   

Abstract

A 7-month-old boy with a high risk ALL harbouring the translocation (4;11) was grafted with an haploidentical bone marrow from paternal origin. At time of relapse, 11 months after BMT, he received donor leukocyte infusions (DLI) which put him in second CR. GVHD and pancytopenia occurred 2 weeks after DLI and were fully reversed with CsA + prednisolone. Six months later, the child continues to be in second CR, off steroid therapy, without any signs of GVHD. Our limited experience indicates that a second CR can be obtained with acceptable toxicity by DLI in very high risk ALL children who have been previously grafted with haploidentical bone marrow cells.

Entities:  

Mesh:

Year:  1994        PMID: 7994252

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  5 in total

Review 1.  Role of donor lymphocyte infusions in relapsed hematological malignancies after stem cell transplantation revisited.

Authors:  Abhinav Deol; Lawrence G Lum
Journal:  Cancer Treat Rev       Date:  2010-04-09       Impact factor: 12.111

2.  NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation.

Authors:  David L Porter; Edwin P Alyea; Joseph H Antin; Marcos DeLima; Eli Estey; J H Frederik Falkenburg; Nancy Hardy; Nicolaus Kroeger; Jose Leis; John Levine; David G Maloney; Karl Peggs; Jacob M Rowe; Alan S Wayne; Sergio Giralt; Michael R Bishop; Koen van Besien
Journal:  Biol Blood Marrow Transplant       Date:  2010-08-10       Impact factor: 5.742

Review 3.  CARs in chronic lymphocytic leukemia -- ready to drive.

Authors:  Chitra Hosing; Partow Kebriaei; William Wierda; Bipulendu Jena; Laurence J N Cooper; Elizabeth Shpall
Journal:  Curr Hematol Malig Rep       Date:  2013-03       Impact factor: 3.952

Review 4.  Graft-versus-host disease after donor leukocyte infusions: presentation and management.

Authors:  Noelle V Frey; David L Porter
Journal:  Best Pract Res Clin Haematol       Date:  2008-06       Impact factor: 3.020

Review 5.  Chimeric antibody receptors (CARs): driving T-cell specificity to enhance anti-tumor immunity.

Authors:  Partow Kebriaei; Susan S Kelly; Pallavi Manuri; Bipulendu Jena; Rineka Jackson; Elizabeth Shpall; Richard Champlin; Laurence J N Cooper
Journal:  Front Biosci (Schol Ed)       Date:  2012-01-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.